The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Breast Cancer With Synchronous Metastases: Trends in Survival During a 14-Year Period
Open accessAbstract
Purpose: Although new drugs were approved during the 1990s for the treatment of metastatic breast cancer, it is not clear whether their use has changed the outcome of patients in daily practice. This study sought to determine whether survival has improved over time for breast cancer patients who had metastases at diagnosis. Patients and Methods: A total of 724 patients have been treated in three French cancer centers for an initially metastatic breast cancer between 1987 and 2000; 343 were diagnosed between 1987 and 1993, and 381 were diagnosed between 1994 and 2000. Tumor characteristics, treatments, and outcomes of these patients were compared by χ 2 test, log-rank test, and Cox regression analysis. Results: Characteristics were not different between the patients diagnosed from 1987 to 1993 and those diagnosed from 1994 to 2000. Ten percent of patients treated from 1987 to 1994 and 58% of patients treated from 1994 to 2000 have received either a taxane or a new aromatase inhibitor. The 3-year overall survival rates were 27% for patients treated from 1987 to 1993 and 44% for patients treated from 1994 to 2000 (P < .001). The treatment period (1994 to 2000 v 1987 to 1993) was a prognostic factor in multivariate analysis (relative risk, 0.6; P < .001). Conclusion: The survival of breast cancer patients presenting with metastases at diagnosis has improved over time. This study strongly suggests that this improvement is related to treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Metastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
Long-term trends in the incidence of and survival with heart failure
Levy, D., Kenchaiah, S., Larson, M. G., Benjamin, E. J., Kupka, M. J., Ho, K. K. L., Murabito, J. M., & Vasan, R. S. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020265 · Cited by 2,152
O’Shaughnessy, J., Miles, D., Vukelja, S., Moiseyenko, V., Ayoub, J.-P., Cervantes, G., Fumoleau, P., Jones, S., Lui, W.-Y., Mauriac, L., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.002 · Cited by 1,081
Ozer, H., Armitage, J. O., Bennett, C. L., Crawford, J., Demetri, G. D., Pizzo, P. A., Schiffer, C. A., Smith, T. J., Somlo, G., Wade, J. C., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3558 · Cited by 1,044
Dombernowsky, P., Smith, I., Falkson, G., Leonard, R., Panasci, L., Bellmunt, J., Bezwoda, W., Gardin, G., Gudgeon, A., Morgan, M., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.453 · Cited by 638
Kaufmann, M., Bajetta, E., Dirix, L. Y., Fein, L. E., Jones, S. E., Zilembo, N., Dugardyn, J.-L., Nasurdi, C., Mennel, R. G., Cervek, J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1399 · Cited by 521
Nabholtz, J.-M., Senn, H. J., Bezwoda, W. R., Melnychuk, D., Deschênes, L., Douma, J., Vandenberg, T. A., Rapoport, B., Rosso, R., Trillet-Lenoir, V., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1413 · Cited by 508
Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., BLOMQVIST, C. P., Vogel, C. L., EIERMANN, W., Wolter, J. M., Steinberg, M., Webster, A., et al. (1998) · PubMed · Cited by 417
Gorecka, D., Gorzelak, K., Sliwinski, P., Tobiasz, M., & Zielinski, J. (1997) · Thorax · doi:10.1136/thx.52.8.674 · Cited by 371
Jassem, J., Pieńkowski, T., Płuzańska, A., Jelic, S., Gorbunova, V., Mrsic-Krmpotic, Z., Berzins, J., Nagykalnai, T., Wigler, N., Renard, J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1707 · Cited by 308
TNM classification of malignant tumors. A comparison between the new (1987) and the old editions
Sobin, L. H., Hermanek, P., & Hutter, R. V. P. (1988) · Cancer · Cited by 222
Arimidex Study Group, Buzdar, A. U., Jonat, W., Howell, A., Jones, S. E., Blomqvist, C. P., Vogel, C. L., Eiermann, W., Wolter, J. M., Steinberg, M., et al. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5 · Cited by 174
Does local surgery have a role in the management of stage IV breast cancer?
Carmichael, A. R., Anderson, E. D. C., Chetty, U., & Dixon, J. M. (2003) · European Journal of Surgical Oncology · doi:10.1053/ejso.2002.1339 · Cited by 78
Chemotherapy for metastatic breast cancer–report of a European expert panel
Crown, J. P., Dieras, V. C., Kaufmann, M., von Minckwitz, G., Kaye, S. B., Leonard, R. C., Marty, M. E., Misset, J. L., Osterwalder, B., & Piccart, M. J. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00927-0 · Cited by 77
THE ROLE OF CHEMOTHERAPY FOR METASTATIC BREAST CANCER
Miller, K. D., & Sledge, G. W. (1999) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70063-0 · Cited by 58
Montella, M., Buonanno, M., Biondi, E., Crispo, A., Marco, M. D., Tamburini, M., Botti, G., Fabbrocini, G., Capasso, I., & D’Aiuto, G. (2000) · Preventive Medicine · doi:10.1006/pmed.1999.0595 · Cited by 9
Cited by
Kopetz, S., Chang, G. J., Overman, M. J., Eng, C., Sargent, D. J., Larson, D. W., Grothey, A., Vauthey, J.-N., Nagorney, D. M., & McWilliams, R. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5278 · Cited by 1,339
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
Cardoso, F., Costa, A., Norton, L., Senkus, E., Aapro, M., André, F., Barrios, C. H., Bergh, J., Biganzoli, L., Blackwell, K. L., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu385 · Cited by 540
“Notwithstanding these advances, median overall survival of patients with ABC is still only 2–3 years, although the range is wide [1–5], and survival may be longer for patients treated in specialized institutions [6].”
BackgroundSelf-citationTherapeutic Targeting of Toll-Like Receptors for Infectious and Inflammatory Diseases and Cancer
O’Neill, L. A. J., Bryant, C. E., & Doyle, S. L. (2009) · Pharmacological Reviews · doi:10.1124/pr.109.001073 · Cited by 427
Pagani, O., Senkus, E., Wood, W., Colleoni, M., Cufer, T., Kyriakides, S., Costa, A., Winer, E. P., Cardoso, F., & on behalf of the ESO-MBC Task Force (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq029 · Cited by 422
Brain Metastases: The HER2 Paradigm
Lin, N. U., & Winer, E. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2478 · Cited by 417
Metadata
- Authors
- Andre, F., Slimane, K., Bachelot, T., Dunant, A., Namer, M., Barrelier, A., Kabbaj, O., Spano, J. P., Marsiglia, H., Rouzier, R., Delaloge, S., & Spielmann, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2004-08-15
- Volume
- 22
- Issue
- 16
- Pages
- 3302-3308
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2140634848
- Cited by
- 394
- References
- 19
- FWCI
- 6.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.